🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Thalidomide

    The First People's Hospital of Lianyungang

    Gastric Cancer

    approved small molecule active

    1 trial

  2. The Placebo used for the clinical trial is a sterile saline solution (0.9% w/v solution of NaCl in water) supplied in 1.25 mL pre-filled glass syringes., Shingrix suspension for injection in pre filled syringe Herpes zoster vaccine (recombinant, adjuvanted), Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Incident dementia

    approved small molecule active

    1 trial

  3. The live attenuated varicella vaccine and the inactivated hepatitis A vaccine

    Sinovac Research and Development Co.,

    Varicella

    approved mab completed

    1 trial

  4. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  5. Thymosin Alpha 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatitis, Acute Necrotizing

    approved small molecule completed

    1 trial

  6. Ticagrelor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Heart Disease

    approved small molecule active

    1 trial

  7. Ticagrelor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  8. Tirofiban hydrochloride sodium chloride injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Branch Atheromatous Disease

    approved small molecule completed

    1 trial

  9. Tirzepatide

    Grace Therapeutics

    Prader-Willi Syndrome

    approved small molecule active

    1 trial

  10. Tirzepatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  11. Tofacitinib and Acitretin Capsules.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Cutaneous Amyloidosis

    approved small molecule active

    1 trial

  12. Topiramate

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Alcohol Dependence

    approved small molecule active

    1 trial

  13. Topiramate

    United Therapeutics Europe Ltd

    Alcohol Dependence

    approved small molecule completed

    1 trial

  14. Transdermal Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    approved small molecule terminated

    1 trial

  15. Transdermal nicotine patch

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    approved small molecule completed

    1 trial

  16. Transmucosal Buprenorphine

    Indivior Pty Ltd

    Moderate to Severe Opioid-use Disorder

    approved small molecule completed

    1 trial

  17. Treatment group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypertension

    approved small molecule completed

    1 trial

  18. Triamcinolone acetonide-Ketorolac-Ropivacaine

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    approved small molecule active

    1 trial

  19. Trimetazidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Heart Disease

    approved small molecule active

    1 trial

  20. Triple combination therapy group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  21. Triptergium Wilfordii

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Psoriasis Vulgaris

    approved small molecule active

    1 trial

  22. Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  23. Two doses of quadrivalent influenza vaccine

    Sinovac Research and Development Co.,

    Seasonal Influenza

    approved mab completed

    1 trial

  24. USTEKINUMAB, USTEKINUMAB, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources